ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 316 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is 0.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $28,127 | -9.5% | 1,100 | 0.0% | 0.00% | – |
| Q1 2024 | $31,064 | -95.4% | 1,100 | -89.2% | 0.00% | -100.0% |
| Q1 2021 | $674,000 | -19.2% | 10,159 | -6.5% | 0.00% | 0.0% |
| Q4 2020 | $834,000 | +73.8% | 10,862 | -2.6% | 0.00% | +100.0% |
| Q3 2020 | $480,000 | -0.4% | 11,149 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $482,000 | -64.1% | 11,149 | -76.1% | 0.00% | -66.7% |
| Q1 2020 | $1,342,000 | +89.3% | 46,670 | +317.6% | 0.01% | +200.0% |
| Q4 2019 | $709,000 | +123.7% | 11,176 | -0.6% | 0.00% | +100.0% |
| Q3 2019 | $317,000 | -89.3% | 11,247 | -89.9% | 0.00% | -90.0% |
| Q2 2019 | $2,958,000 | +43.0% | 111,622 | -1.0% | 0.01% | +25.0% |
| Q1 2019 | $2,068,000 | +45.9% | 112,723 | -1.3% | 0.01% | +33.3% |
| Q4 2018 | $1,417,000 | -7.6% | 114,160 | +42.7% | 0.01% | 0.0% |
| Q3 2018 | $1,534,000 | +41.0% | 80,000 | 0.0% | 0.01% | +50.0% |
| Q2 2018 | $1,088,000 | – | 80,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $93,815,000 | 51.06% |
| Aquilo Capital Management, LLC | 436,514 | $12,559,000 | 4.90% |
| Vivo Capital, LLC | 768,674 | $22,115,000 | 2.00% |
| ACUTA CAPITAL PARTNERS, LLC | 109,700 | $3,156,000 | 1.53% |
| Prosight Management, LP | 104,737 | $3,013,000 | 1.41% |
| Capital Impact Advisors, LLC | 84,537 | $2,432,000 | 1.02% |
| Artal Group S.A. | 600,000 | $17,262,000 | 0.73% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 62,000 | $1,784,000 | 0.48% |
| Quantitative Investment Management, LLC | 150,401 | $4,327,000 | 0.47% |
| OAK RIDGE INVESTMENTS LLC | 131,502 | $3,784,000 | 0.39% |